Comparison of the Performance and Effectiveness of Two Transfusion-Saving Devices: Cell-Saver and SAME
NCT ID: NCT06766032
Last Updated: 2025-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
304 participants
OBSERVATIONAL
2021-06-05
2024-07-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Platelet Count and Function After Usage of Two Different Cell Saver Devices During Liver Transplant Surgery
NCT06357455
Platelet Function After Cardiac Surgery.
NCT06405516
Platelet and Autotransfusion Device in Cardiac Surgery
NCT06629311
AutoTransfusion Versus TRAnsfusion in Cancer Surgery
NCT05452538
Intraoperative Cell Saver Autotransfusion Use for Major Surgical Oncology Operations.
NCT00708513
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main outcome measure is the difference between the preoperative and immediate postoperative platelet counts (delta platelet) for each patient between the SAME and Cell-Saver groups.
° Secondary outcomes of the study:
The secondary outcomes are to evaluate, from the preoperative period until day 28 postoperatively:
* The post-operative platelet count between days 1 and 5
* The frequency of perioperative and postoperative transfusions, including the number and type of blood products transfused
* The use of derivative medications (fibrinogen, prothrombin complex concentrates)
* The volume of postoperative bleeding
* The frequency of postoperative events (infectious, renal, thromboembolic, hemorrhagic)
* The length of stay in the intensive care unit and in the hospital
* The frequency of treatment for postoperative anemia with iron or erythropoiesis-stimulating agents.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cell-Saver group
Patients for whom the Cell-saver device is used during cardiac surgery.
CELL-Saver
The Cell-saver device allows for red blood cell reinfusion during cardiac surgery.
SAME group
Patients for whom the SAME device is used during cardiac surgery.
SAME
The SAME device allows for red blood cell and platelet reinfusion during cardiac surgery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CELL-Saver
The Cell-saver device allows for red blood cell reinfusion during cardiac surgery.
SAME
The SAME device allows for red blood cell and platelet reinfusion during cardiac surgery.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with sepsis, a malignant tumor at the surgical site, or contamination of recovered blood with biological fluids/antiseptics/distilled water/local antibiotics/hemostatic agents.
* Organ transplantation and planned circulatory support in the preoperative period
* Uni-bi-ventricular artificial heart
* Reoperation in a patient already included in the study
* Patient refusing blood transfusion
* Pregnant women
* Legally Protected adults
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nantes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mickaël Vourc'h, MD-PhD
Role: PRINCIPAL_INVESTIGATOR
Nantes HU
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Nantes
Nantes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AR_2024_001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.